Seth Alexander, Ph.D.

Director of RNA Technologies at Prime Medicine

Speaker

Seth Alexander is a highly experienced organic chemist with a Ph.D and over 6 years of industry experience. His career in oligonucleotide therapeutics began as a postdoc where he co-invented a novel RNA labeling technology to site–specifically and covalently modify RNA. His first industry position was at Intellia Therapeutics (2017-2021) where he focused on developing Cas9 mRNA that made its way into clinical programs as well as guide RNA sequence and chemical modifications aimed at improving the therapeutic Index of Intellia's portfolio. Seth spent one year at Resilience (2021-2022) in process development building platform processes for the nucleic acids Franchise, before joining Prime Medicine in April of 2022. Seth's current role is to lead Prime’s RNA Technologies and Protein Sciences Teams which oversee the design and development of RNA and Protein prime editing components leveraged across the company.